Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9870201 | 0.79 | ALDH1A1 (0.35) | CYP2A6NPC1MAPTALDH1A1GLA | |
| SCHEMBL558134 | 0.74 | CYP1A2 (0.43) | CYP1A2CYP2A6NPC1MAPTALDH1A1 | |
| SCHEMBL9479758 | 0.74 | MIF (0.31) | MAPTALDH1A1GLAHPGDACHE | |
| SCHEMBL3643104 | 0.74 | ALDH1A1 (0.34) | CYP2A6MAPTALDH1A1GLAHPGD | |
| SCHEMBL1879034 | 0.74 | PDPK1 (0.43) | CYP1A2NPC1MAPTALDH1A1GLA | |
| SCHEMBL636922 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL637845 | 0.74 | HSD17B10 (0.39) | CYP1A2HPGD | |
| SCHEMBL637345 | 0.72 | MEN1 (0.43) | NPC1MAPTALDH1A1HPGD | |
| SCHEMBL21436333 | 0.70 | F2RL3 (0.32) | — | |
| SCHEMBL6841772 | 0.69 | HTR2A (0.35) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829466-B2 | Stilbene derivative and preparation method thereof | BEIJING INSTITUTE OF TECHNOLOGY (CN) | 2020-11-10 | — | — | US | claimed |
| US-20200148662-A1 | NOVEL STILBENE DERIVATIVE AND PREPARATION METHOD THEREOF | BEIJING INSTITUTE OF TECHNOLOGY (CN) | 2020-05-14 | — | — | US | claimed |
| EP-2563796-B1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-18 | — | — | EP | claimed |
| US-8481555-B2 | Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | claimed |
| EP-2563796-A1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120108596-A1 | Aza-Bicyclic Amine N-Oxide Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligand Pro-Drugs | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-03 | — | — | US | claimed |
| WO-2011137313-A1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | claimed |
| US-10829466-B2 | Stilbene derivative and preparation method thereof | BEIJING INSTITUTE OF TECHNOLOGY (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20200148662-A1 | NOVEL STILBENE DERIVATIVE AND PREPARATION METHOD THEREOF | BEIJING INSTITUTE OF TECHNOLOGY (CN) | 2020-05-14 | — | — | US | disclosed |
| EP-2563796-B1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8481555-B2 | Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2563796-A1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120108596-A1 | Aza-Bicyclic Amine N-Oxide Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligand Pro-Drugs | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-03 | — | — | US | disclosed |
| WO-2011137313-A1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829466-B2 | Stilbene derivative and preparation method thereof | STS, F12, GLB1 | CYP1A2 210/4885CYP2A6 134/4885NPC1 1617/4885 |
| US-20120108596-A1 | Aza-Bicyclic Amine N-Oxide Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligand Pro-Drugs | CHRNA7, CHRNA5, CHRNA9 | CYP1A2 558/4885CYP2A6 863/4885NPC1 1302/4885 |
| US-20200148662-A1 | NOVEL STILBENE DERIVATIVE AND PREPARATION METHOD THEREOF | STS, F12, STK38L | CYP1A2 325/4885CYP2A6 182/4885NPC1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.